

1. Please click [here](#) [1] to download the group picture of your seminar.

2. Presentations:

1. Therapeutic drug monitoring for all drugs and for all patients? [2]

Dr Ute Blassmann [3], Heidelberg University Hospital, Germany

2. Do we need therapeutic drug monitoring for beta lactams or can we just use prolonged infusions? [4]

Dr Ute Blassmann [3], Heidelberg University Hospital, Germany

3. The impact of PK/PD for clinical decisions [5]

Dr Anouk Muller [6], HaaglandenMC, The Hague and ErasmusMC, Rotterdam

4. MIC directed therapy: why, when and what are the pitfalls? [7]

Dr Anouk Muller [6], HaaglandenMC, The Hague and ErasmusMC, Rotterdam

5. Interactive Part – clinical cases – PK/PD [8]

Prof Dr Isabel Spiet [9], UZ Leuven, Belgium

Dr Peter Declercq [10], University Hospitals Leuven, Belgium

6. Implementation of check of medication appropriateness: what can the computer do for ABS? [11]

Prof Dr Isabel Spiet [9], UZ Leuven, Belgium

7. Antifungal therapy: what comes out of the pipeline in the near future? [12]

*Prof William Hope** [13], University of Liverpool, United Kingdom

8. TDM and PK/PD in antifungal therapy: when and why? [14]

*Prof William Hope** [13], University of Liverpool, United Kingdom

9. Antimicrobial prophylaxis in HSCT-patients: guidelines and evidence [15]

Dr Philipp Wohlfarth [16], Medical University of Vienna, Austria

10. Hygiene measures, isolation and therapy [17]

Prof Dr Annette Schuermans [18], University Hospitals Leuven, Belgium

11. What's really new in antibiotic therapy [19]

Prof Dr Martin J. Hug [20], Institute of Pharmaceutical Sciences, University of Freiburg,

Germany

12. Interactive Part - PKPD & TDM of antifungals [21]

Prof Dr Isabel Spiert [9], UZ Leuven, Belgium

Prof William Hope* [13], University of Liverpool, United Kingdom

Last update: 25 September 2019

Links

[1] https://www.eahp.eu/sites/default/files/s1_2.png [2]

https://www.eahp.eu/sites/default/files/1._therapeutic_drug_monitoring_for_all_drugs_and_for_all_patients.pdf

[3] <http://www.eahp.eu/content/dr-ute-blassmann> [4]

https://www.eahp.eu/sites/default/files/2._do_we_need_therapeutic_drug_monitoring_for_beta_lactams_or_can_we

[5] https://www.eahp.eu/sites/default/files/3._the_impact_of_pkpd_for_clinical_decisions_0.pdf [6]

<https://www.eahp.eu/content/dr-anouk-muller> [7]

https://www.eahp.eu/sites/default/files/4._mic_directed_therapy_why_when_and_what_are_the_pitfalls.pdf

[8] https://www.eahp.eu/sites/default/files/5._interactive_part_-_clinical_cases_-_pkpd.pdf [9]

<http://www.eahp.eu/content/prof-dr-isabel-spiert> [10] <http://www.eahp.eu/content/dr-peter-declercq> [11]

https://www.eahp.eu/sites/default/files/6._implementation_of_check_of_medication_appropriateness_what_can_the
[12]

https://www.eahp.eu/sites/default/files/7._antifungal_therapy_what_comes_out_of_the_pipeline_in_the_near_future.

[13] <http://www.eahp.eu/content/prof-william-hope> [14]

https://www.eahp.eu/sites/default/files/8._tdm_and_pkpd_in_antifungal_therapy_when_and_why.pdf [15]

https://www.eahp.eu/sites/default/files/9._antimicrobial_prophylaxis_in_hsctpatients_guidelines_and_evidence.pdf

[16] <http://www.eahp.eu/content/dr-philipp-wohlforth> [17]

https://www.eahp.eu/sites/default/files/10._hygiene_measures_isolation_and_therapy.pdf [18]

<http://www.eahp.eu/content/prof-dr-annette-schuemans> [19]

https://www.eahp.eu/sites/default/files/11._whats_really_new_in_antibiotic_therapy_mjh.pdf [20]

<http://www.eahp.eu/content/prof-dr-martin-j-hug-0> [21]

https://www.eahp.eu/sites/default/files/12._interactive_part_-_pkpd_tdm_of_antifungals.pdf